Investigational New Drugs Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

FDA Lifts Clinical Hold on Investigational Lenacapavir for the Treatment and Prevention of HIV
FOSTER CITY, Calif.--(BUSINESS WIRE)--May 16, 2022-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced the U.S. Food and Drug Administration (FDA) has lifted the clinical hold placed on the company’s Investigational New Drug Application... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - May 16, 2022 Category: Pharmaceuticals Source Type: clinical trials

Ascletis Announces U.S. IND Approval of ASC22 (Envafolimab), a Subcutaneously Administered PD-L1 Antibody for Functional Cure of Chronic Hepatitis B
HANGZHOU and SHAOXING, China, Jan. 17, 2022. Ascletis Pharma Inc. announced today the Investigational New Drug (IND) application approval by U.S. Food and Drug Administration (FDA) and initiation of global development of ASC22 (Envafolimab), a... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - January 17, 2022 Category: Pharmaceuticals Source Type: clinical trials

Merck Announces Clinical Holds on Studies Evaluating Islatravir for the Treatment and Prevention of HIV-1 Infection
KENILWORTH, N.J.--(BUSINESS WIRE) December 13, 2021 -- Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has placed clinical holds on the investigational new drug... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - December 13, 2021 Category: Pharmaceuticals Source Type: clinical trials

Study to Compare the Effects of Repeated Doses of an Investigational New Drug (PF-06946860) and a Placebo on Appetite in Participants With Advanced Cancer and Anorexia
Conditions: Non-small Cell Lung Cancer; Pancreatic Cancer; Colorectal Cancer; Prostate Cancer; Breast Cancer; Ovarian Cancer; Loss of Appetite; Fatigue; Cachexia; Anorexia Interventions: Drug: PF-06946860; Drug: Placebo for PF-06946860 Sponsor: Pfizer Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 17, 2021 Category: Research Source Type: clinical trials

Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial
In this study, patients with confirmed positive COVID-19 tests receive imatinib for a total of 14 days; 400 mg orally daily Days 1-14. Imatinib 400 mg tablets will be encapsulated using size 000 capsules and cellulose microcrystalline filler. For patients on ventilator or ECMO, imatinib will be given as oral suspension (40 mg/mL). To make the oral suspension, imatinib tablets will be crushed and mixed in Ora-sweet solution to yield a concentration of 40 mg/mL suspension by pharmacy. Additionally, in the absence of supportive microbiological testing results, we confirm that the in-use stability period for the prepared imati...
Source: Trials - October 28, 2020 Category: Research Source Type: clinical trials